ChemLifeIntel
Access
ChemLifeIntel/Companies/Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc.

HIGH RISKHQ: — · Private · Founded —
LISTINGPrivateFOUNDED0
FOCUS THERAPY AREAS
Manufacturer
COMPANY INTELLIGENCE SNAPSHOTlive
0
Manufacturing Sites
2
Intelligence Briefs
0
Active Regulatory Actions
—
HQ Country
NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ
View regulatory detail

INTELLIGENCE

Showing 2 of 2 briefs on Pacira Pharmaceuticals, Inc.
REGULATORY INTELLIGENCE·Recall

Pacira Pharmaceuticals Recalls 40,517 Zilretta Kits Over Failed Dissolution Specifications

Pacira Pharmaceuticals, Inc. has initiated a Class II recall for 40,517 kits of Zilretta (triamcinolone acetonide extended-release injectable suspension) due to failed dissolution specifications. This voluntary, firm-initiated action impacts US nationwide distribution, necessitating immediate review of inventory and potential supply chain adjustments for buyers of intra-articular corticosteroids.

90-Day Activity
Pacira Pharmaceuticals,ZILRETTA
MKMeera Krishnan· Senior Regulatory Intelligence Analyst
2024-07-03
REGULATORY INTELLIGENCE·Recall

FDA Class II Recall: Pacira's ZILRETTA Faces Nationwide Disruption Due to Stability Failure

Pacira Pharmaceuticals, Inc. has initiated a Class II nationwide recall of 43,768 kits of ZILRETTA (triamcinolone acetonide extended-release injectable suspension). This action, triggered by failed stability specifications, mandates immediate attention from procurement directors and supply chain VPs to mitigate disruption and assess the implications for product quality and patient access across the U.S.

90-Day Activity
Pacira Pharmaceuticals,ZILRETTA
RMRohan Mehta· Senior Supply Chain Intelligence Analyst
2024-06-19